JP2006514636A - 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 - Google Patents

抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 Download PDF

Info

Publication number
JP2006514636A
JP2006514636A JP2004557434A JP2004557434A JP2006514636A JP 2006514636 A JP2006514636 A JP 2006514636A JP 2004557434 A JP2004557434 A JP 2004557434A JP 2004557434 A JP2004557434 A JP 2004557434A JP 2006514636 A JP2006514636 A JP 2006514636A
Authority
JP
Japan
Prior art keywords
wta
infection
aureus
antibody
staphylococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004557434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514636A5 (enExample
Inventor
コカイ−クン，ジョン・フィッツジェラルド
クリスティアン，サッシャ・エイ
ヴァイデンマイアー，クリストファー
ペスヒェル，アンドレアス
Original Assignee
バイオシネクサス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオシネクサス インコーポレーテッド filed Critical バイオシネクサス インコーポレーテッド
Publication of JP2006514636A publication Critical patent/JP2006514636A/ja
Publication of JP2006514636A5 publication Critical patent/JP2006514636A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2004557434A 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 Pending JP2006514636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43022502P 2002-12-02 2002-12-02
PCT/US2003/038132 WO2004050846A2 (en) 2002-12-02 2003-12-01 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines

Publications (2)

Publication Number Publication Date
JP2006514636A true JP2006514636A (ja) 2006-05-11
JP2006514636A5 JP2006514636A5 (enExample) 2007-06-07

Family

ID=32469426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557434A Pending JP2006514636A (ja) 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸

Country Status (6)

Country Link
US (1) US20040247605A1 (enExample)
EP (1) EP1567868A4 (enExample)
JP (1) JP2006514636A (enExample)
AU (2) AU2003298770A1 (enExample)
CA (1) CA2507711A1 (enExample)
WO (1) WO2004050846A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014237687A (ja) * 2007-08-31 2014-12-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
JP2016525343A (ja) * 2013-05-31 2016-08-25 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
JP2016532433A (ja) * 2013-05-31 2016-10-20 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
JP2019519509A (ja) * 2016-05-18 2019-07-11 ゲンマブ ビー．ブイ． 感染性疾患の治療における抗体およびその使用方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US20070071682A1 (en) * 2005-08-22 2007-03-29 Kokai-Kun John F Methods for testing vaccine candidates against bacterial infection in rodents
CA2625580A1 (en) * 2005-10-11 2007-04-26 Iogenetics, Llc Targeted biocides
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009151561A2 (en) * 2008-06-12 2009-12-17 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
KR20110124060A (ko) * 2010-05-10 2011-11-16 부산대학교 산학협력단 Ｗｔａ를 유효성분으로 함유하는 백신 조성물
WO2013071409A1 (en) 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
CN103383354B (zh) * 2012-05-03 2016-11-09 北京博迈世纪生物技术有限公司 一种检测肠毒素sea的磁微粒化学发光试剂盒的检测方法
KR20150024315A (ko) * 2012-05-07 2015-03-06 재단법인 목암생명공학연구소 포도상구균 감염 예방용 백신 조성물
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
TWI632157B (zh) * 2013-05-31 2018-08-11 建南德克公司 抗壁磷壁酸抗體（ａｎｔｉ－ｗａｌｌ ｔｅｉｃｈｏｉｃ ａｃｉｄ ａｎｔｉｂｏｄｉｅｓ）及結合物
WO2015183041A1 (ko) * 2014-05-29 2015-12-03 주식회사 녹십자 포도상구균 감염 질환의 예방 또는 치료용 조성물
KR20170086536A (ko) * 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
US5139933A (en) * 1989-09-26 1992-08-18 Vicam, L.P. Assay method for detecting listeria
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5290707A (en) * 1991-11-25 1994-03-01 The United States Of America As Represented By The Secretary Of The Army Method for detection of microorganisms
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
JP3814290B2 (ja) * 1993-12-09 2006-08-23 エスクナー，ハインリッヒ 抗原用のアジュバントおよびその製法ならびに用途
US6350597B1 (en) * 1994-01-13 2002-02-26 E. I. Du Pont De Nemours & Company Riboflavin synthase genes and enzymes and methods of use
US6203997B1 (en) * 1994-06-08 2001-03-20 Sepsis, Inc. Quantitation of analytes in whole blood
EP0807185B9 (en) * 1995-01-30 2002-12-11 Lunamed AG Antitumor preparations containing a lipoteichoic acid from steptococcus
ATE328069T1 (de) * 1995-10-13 2006-06-15 Harvard College Phosphopantethenyltransferasen und deren verwendungen
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5889171A (en) * 1997-07-18 1999-03-30 Smithkline Beecham Corporation TarF
SK732000A3 (en) * 1997-07-23 2001-03-12 Ambi Inc Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
ES2281977T3 (es) * 1998-12-22 2007-10-01 Microscience Limited Proteinas de estreptococo del grupo b y su utilizacion.
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US6365156B1 (en) * 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
US6974700B2 (en) * 1999-06-14 2005-12-13 Martin Levine Kit for use in predicting refractory periodontal disease
US20020051793A1 (en) * 2000-09-12 2002-05-02 Drabick Joseph J. Lipoteichoic acid immunogenic compositions and methods of making and using thereof
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
AU2003203079B9 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
EP2228379A1 (en) * 2003-04-25 2010-09-15 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
US7422755B2 (en) * 2004-01-15 2008-09-09 The United States Of America As Represented By The Department Of Health And Human Services Antimultiorganism glycoconjugate vaccine
KR100596443B1 (ko) * 2004-04-27 2006-07-05 주식회사 하이닉스반도체 다수 뱅크 구조 디램을 위한 리프레시 제어회로 및 그 방법
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
JP2008537885A (ja) * 2005-04-15 2008-10-02 ノース・キャロライナ・ステイト・ユニヴァーシティ 細菌の付着およびストレス耐性を修飾する方法および組成物
US7521535B2 (en) * 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014237687A (ja) * 2007-08-31 2014-12-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
JP2017002080A (ja) * 2007-08-31 2017-01-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
JP2016525343A (ja) * 2013-05-31 2016-08-25 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
JP2016532433A (ja) * 2013-05-31 2016-10-20 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
JP2019519509A (ja) * 2016-05-18 2019-07-11 ゲンマブ ビー．ブイ． 感染性疾患の治療における抗体およびその使用方法
JP2022105143A (ja) * 2016-05-18 2022-07-12 ゲンマブ ビー．ブイ． 感染性疾患の治療における抗体およびその使用方法

Also Published As

Publication number Publication date
WO2004050846A3 (en) 2005-03-17
AU2003298770A2 (en) 2004-06-23
AU2010200341A1 (en) 2010-02-18
CA2507711A1 (en) 2004-06-17
EP1567868A4 (en) 2008-02-06
US20040247605A1 (en) 2004-12-09
WO2004050846A8 (en) 2004-09-16
AU2003298770A1 (en) 2004-06-23
WO2004050846A2 (en) 2004-06-17
EP1567868A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
AU2010200341A1 (en) Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines
US7777017B2 (en) Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
CN113490686A (zh) 病原体结合蛋白
EP2464665B1 (en) Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
WO2020098701A1 (zh) 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
JP2010013454A (ja) グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体
AU2009202762A1 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
de Freitas et al. Promising targets for immunotherapeutic approaches against Acinetobacter baumannii
Kahler et al. Structure-function relationships of the Neisserial EptA enzyme responsible for phosphoethanolamine decoration of lipid A: rationale for drug targeting
WO2014142117A1 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
KR20150024315A (ko) 포도상구균 감염 예방용 백신 조성물
WO2021079986A1 (ja) バクテリオファージ組成物
US7544483B2 (en) Method for the production of protamine
JP2017518373A (ja) スタフィロコッカス・アウレウス感染疾患の予防または治療用組成物
Ebert et al. Development of a rat central venous catheter model for evaluation of vaccines to prevent Staphylococcus epidermidis and Staphylococcus aureus early biofilms
CN111565745B (zh) 细菌感染症用鸵鸟抗体
WO2021079536A1 (ja) バクテリオファージ組成物
Heilmann et al. Molecular basis of biofilm formation by Staphylococcus epidermidis
JP2019510519A5 (enExample)
Bavro Lipid A: Rationale for Drug Targeting
Grousd Defining Staphylococcus aureus Virulence Factors in Bacterial Pneumonia and Influenza Super-Infection
JP2006502968A (ja) 細菌性コラーゲン結合タンパク質に対して交差反応性のモノクロナール抗体
Shahrooei et al. Identification of potential targets for vaccination against Staphylococcus epidermidis biofilms
CN104861072A (zh) 抗eLtaS蛋白的人源化抗体与应用
Xie Bactericidal activity and improvement of therapeutic potency of recombinant antibody fragments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110524